Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

Both GLP-1 receptor agonists (GLP-1RA) and SGLT-2 inhibitors (SGLT-2I) are newer classes of anti-diabetic agents that lower HbA1c moderately and decrease body weight and systolic blood pressure (SBP) modestly. Combination therapy with GLP-1RA plus SGLT-2I have shown a greater reduction in HbA1c, bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Awadhesh Kumar, Singh, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258221/
https://www.ncbi.nlm.nih.gov/pubmed/35979179
http://dx.doi.org/10.4330/wjc.v14.i6.329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258221/
https://www.ncbi.nlm.nih.gov/pubmed/35979179
http://dx.doi.org/10.4330/wjc.v14.i6.329

Ejemplares similares